长春高新(000661.SZ)：GenSci134注射液境内生产药品注册临床试验申请获批准

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received approval from the National Medical Products Administration for the clinical trial application of GenSci134 injection, a domestically produced drug [1] Group 1: Company Developments - Jinsai Pharmaceutical's GenSci134 injection is an independently developed Class 1 biological product intended for the treatment of growth hormone deficiency (GHD), including adult growth hormone deficiency (AGHD) and pediatric growth hormone deficiency (PGHD) [1] - The current application specifically targets idiopathic short stature (ISS) patients [1]